Advanced Biomarker Testing: How Does This Matter Clinically?

Advanced Biomarker Testing: How Does This Matter Clinically? is organized by Obesity Medicine Association (OMA).

Presentation Date:Apr 22, 2017
Expiration Date: Apr 15, 2020 12:00 AM

Credits:
AMA PRA Category 1 Credit(s): 1.00
Participation Credit(s): 1.00

Description:
Dr. Dall will be discussing what advanced lipids and inflammatory biomarkers mean along with their roles.

Objectives:
• Discuss the utility of novel cardiovascular risk markers in primary vs. secondary prevention of cardiovascular disease (CVD) and among patients with additional comorbidities
• Describe the differences between LDL cholesterol, Apo B and LDL-P and the respective lipid subclasses and their role in the atherogenicity of lipid profiles
• Explain the roles of pharmaceutical and lifestyle interventions in CVD risk reduction
• List ways in which advanced lipid panels and inflammatory markers may refine dietary interventions to maximize CVD risk reduction

Additional details will be posted as soon as information is available.